{"id":"W4392091243","doi":"10.1200/jco.23.01601","title":"First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":216,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Gastroesophageal Junction; Esophageal adenocarcinoma; Chemotherapy; Internal medicine; Gastric adenocarcinoma; Adenocarcinoma; Gastroenterology; Phases of clinical research; Oncology; Surgery; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01213718,0.001152402,0.002621566,0.0004655003,0.0009518975,0.002177961,0.000753196,0.002211245,0.002923769],"category_scores_gemma":[0.006378253,0.0004499918,0.004323524,0.0005906316,0.0007275371,0.001431414,0.0007252221,0.00394393,0.0009702154],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001162968,"about_ca_system_score_gemma":0.001809498,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001074984,"about_ca_topic_score_gemma":0.002131691,"domain_scores_codex":[0.9976982,0.001401007,0.000147448,0.0002030747,0.0002658709,0.0002844094],"domain_scores_gemma":[0.9953577,0.001090467,0.001305197,0.0006473027,0.0004403592,0.001158941],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8778551,0.01147076,0.01591451,0.001300344,0.006145441,0.0002195172,0.0001928617,0.003341121,0.006429599,0.0004635649,0.01223224,0.06443485],"study_design_scores_gemma":[0.6290436,0.2464458,0.09260232,0.0003806162,0.006979521,0.0005343959,0.0001156225,0.004250744,0.004608443,0.0014739,0.01344548,0.000119582],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9451014,0.01783681,0.003658223,0.002268083,0.0009154336,0.007942238,0.01109366,0.0004114722,0.01077267],"genre_scores_gemma":[0.9644786,0.003276316,0.002355578,0.00338966,0.0004768563,0.006694552,0.01352389,0.0001090408,0.005695629],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01213718,"threshold_uncertainty_score":0.0641883,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06358621870465926,"score_gpt":0.4120272378043416,"score_spread":0.3484410190996823,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}